

Special Issue

Robot-Assisted Radical Prostatectomy for Urologic Cancer: State of the Art

Message from the Guest Editor

Prostate cancer (PCa) is the second most common malignancy diagnosed in men worldwide and radical prostatectomy (RP) remains the mainstay therapy for organ-confined disease. The technological revolution, along with sophisticated improvements in surgical techniques, has led to the predominance of robotic surgery over previous RP approaches. Currently, in most advanced health systems, robot-assisted radical prostatectomy (RALP) is the most prevalent surgical approach in PCa therapy. Despite all the efforts and obvious progress, a third of patients subjected to RALP develop biochemical failure. Understanding the best candidates for surgery, in whom it could, and should, be omitted due to a low risk of cancer progression or unacceptable risk of morbidity, and in whom it should be preceded with neoadjuvant therapy or supplemented with radiation or systemic management remain still to be seen. This Special Issue will highlight the role of robot-assisted surgery in the current and future landscape of prostate cancer therapy. A number of clinical applications and their utility will be presented and discussed.

Guest Editor

Prof. Dr. Jakub Dobruch
Centrum Medyczne Kształcenia Podyplomowego, Warsaw, Poland

Deadline for manuscript submissions

closed (30 September 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/195759

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)